TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

Products, services, technology

Proprietary drug discovery and development platform to explore novel resistance-breaking therapies that can be combined with existing cancer drugs to prevent resistance development in several types of cancer. Two parallel drug development programs are ongoing.

Cooperation possibilities

Industrial partnerships as well as academic research collaborations or consortia

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    1-9
Key business